Fabio
89 lines
5.0 KiB
Markdown
89 lines
5.0 KiB
Markdown
---
|
||
type: "Bill"
|
||
title: "Active Pharmaceutical Ingredient Manufacturing Grant Fund; established."
|
||
description: "Active Pharmaceutical Ingredient Manufacturing Grant Fund. Establishes the Active Pharmaceutical Ingredient Manufacturing Grant Fund to provide grant installment awards between July 1, 2026, and July 1, 2045, in an amount not to exceed $15 million per fiscal year and in an aggregate amount not to exceed $130 million, to a qualified company that (i) engages in the manufacture of pharmaceutical substances, (ii) executes a memorandum of understanding with the Commonwealth, and (iii) is expected to make a capital investment of at least $2,148,793,019 and create and maintain at least 468 new full-time jobs. This bill is identical to HB 800."
|
||
jurisdiction: "us/states/va"
|
||
legislature: "Virginia General Assembly"
|
||
session: "2026"
|
||
identifier: "SB 404"
|
||
citation: "Virginia SB 404 (2026)"
|
||
classification: ["bill"]
|
||
subjects: []
|
||
status: "enacted"
|
||
primary_sponsors: ["L. Louise Lucas"]
|
||
version_count: 2
|
||
action_count: 27
|
||
vote_count: 5
|
||
first_action: "2026-01-13"
|
||
last_action: "2026-04-13"
|
||
source: "openstates"
|
||
source_identifier: "ocd-bill/252d9804-550b-49fc-8067-8da5ea2d0c06"
|
||
source_url: "https://lis.virginia.gov/bill-details/20261/SB404"
|
||
source_hash: "77d283b789675da8bd572deca58baa24c765c304abf4f0fc7f8583a592738946"
|
||
vintage: "2026-07-01"
|
||
source_snapshot: "https://data.openstates.org/daily/2026-07-01/public.pgdump"
|
||
retrieved_at: "2026-07-06"
|
||
confidence: "reported"
|
||
tags: ["legislation", "bill", "us-va"]
|
||
---
|
||
|
||
# Virginia SB 404 (2026) — Active Pharmaceutical Ingredient Manufacturing Grant Fund; established.
|
||
|
||
Active Pharmaceutical Ingredient Manufacturing Grant Fund. Establishes the Active Pharmaceutical Ingredient Manufacturing Grant Fund to provide grant installment awards between July 1, 2026, and July 1, 2045, in an amount not to exceed $15 million per fiscal year and in an aggregate amount not to exceed $130 million, to a qualified company that (i) engages in the manufacture of pharmaceutical substances, (ii) executes a memorandum of understanding with the Commonwealth, and (iii) is expected to make a capital investment of at least $2,148,793,019 and create and maintain at least 468 new full-time jobs. This bill is identical to HB 800.
|
||
|
||
## Version chain
|
||
|
||
The bill's text revisions, in order — the diff chain from filing to enrollment.
|
||
|
||
1. **Introduced** (filed) — [source](https://lis.blob.core.windows.net/files/1089935.PDF)
|
||
2. **Enrolled** (enrolled) — [source](https://lis.blob.core.windows.net/files/1181661.PDF)
|
||
|
||
## Votes
|
||
|
||
- Constitutional reading dispensed R — **40–0** (pass) · upper
|
||
- Passage R — **38–0** (pass) · upper
|
||
- Reported from Finance and Appropriations — **14–0** (pass) · upper
|
||
- H VOTE: — **97–0** (pass) · lower
|
||
- Reported from Appropriations — **22–0** (pass) · lower
|
||
|
||
## Sponsors
|
||
|
||
- L. Louise Lucas — primary (person)
|
||
|
||
## Timeline
|
||
|
||
The legislative action history — every referral, reading, and vote.
|
||
|
||
- **2026-01-13** Prefiled and ordered printed; Offered 01-14-2026 26102909D `filing, introduction`
|
||
- **2026-01-13** Referred to Committee on Finance and Appropriations `referral-committee`
|
||
- **2026-01-23** Fiscal Impact Statement from Department of Planning and Budget (SB404)
|
||
- **2026-01-27** Reported from Finance and Appropriations (14-Y 0-N) `committee-passage`
|
||
- **2026-01-28** Rules suspended
|
||
- **2026-01-28** Constitutional reading dispensed Block Vote (on 1st reading) (40-Y 0-N 0-A)
|
||
- **2026-01-28** Passed by for the day Block Vote (Voice Vote)
|
||
- **2026-01-28** Passed by for the day
|
||
- **2026-01-29** Read second time `reading-2`
|
||
- **2026-01-29** Engrossed by Senate (Voice Vote)
|
||
- **2026-01-30** Read third time and passed Senate (38-Y 0-N 0-A) `passage, reading-3`
|
||
- **2026-02-04** Placed on Calendar
|
||
- **2026-02-04** Read first time `reading-1`
|
||
- **2026-02-04** Referred to Committee on Appropriations `referral-committee`
|
||
- **2026-02-18** Assigned HAPP sub: Commerce Agriculture & Natural Resources `referral-committee`
|
||
- **2026-02-20** Reported from Appropriations (22-Y 0-N) `committee-passage`
|
||
- **2026-02-24** Read second time `reading-2`
|
||
- **2026-02-25** Read third time `reading-3`
|
||
- **2026-02-25** Passed House (97-Y 0-N 0-A) `passage`
|
||
- **2026-02-27** Enrolled `enrolled`
|
||
- **2026-02-27** Bill text as passed Senate and House (SB404ER) `passage`
|
||
- **2026-02-27** Fiscal Impact Statement from Department of Planning and Budget (SB404)
|
||
- **2026-02-27** Signed by Speaker `passage`
|
||
- **2026-02-27** Signed by President `passage`
|
||
- **2026-03-10** Enrolled Bill communicated to Governor on March 10, 2026 `enrolled, executive-receipt`
|
||
- **2026-03-10** Governor's Action Deadline 11:59 p.m., April 13, 2026 `executive-receipt`
|
||
- **2026-04-13** Approved by Governor-Chapter 822 (effective 7/1/2026) `executive-signature`
|
||
|
||
## Source
|
||
|
||
OpenStates / OpenCivicData bulk snapshot [2026-07-01](https://data.openstates.org/daily/2026-07-01/public.pgdump); origin `ocd-bill/252d9804-550b-49fc-8067-8da5ea2d0c06`. Confidence: reported (aggregated from official Virginia legislature records).
|
||
|